Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., today announced that the National Comprehensive Cancer Network (NCCN) has included the DecisionDx®-UM gene expression profile (GEP) test class results in their new clinical practice guidelines for uveal melanoma. These recommendations, released on March 15, 2018, are the first-ever NCCN guidelines for uveal melanoma, and their publication is an important milestone in the care of patients with this rare eye cancer. The new guidelines